Sign In
Buy BHVN
$13.50
-0.320 (-2.32%)
At Close: Jul 31, 2026
NEW YORK, NY / ACCESS Newswire / March 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
NEW YORK, NY / ACCESS Newswire / March 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE:BHVN)
Biohaven Ltd. Being Investigated on Behalf of Biohaven Ltd.
02:45pm, Friday, 07'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
Bronstein, Gewirtz & Grossman, LLC Encourages Biohaven Ltd. (BHVN) Investors to Inquire about Securities Investigation
10:00am, Friday, 07'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE:BHVN)
Levi & Korsinsky Reminds Shareholders of an Investigation into Biohaven Ltd. (BHVN) Regarding Potential Securities Fraud Allegations
10:30am, Thursday, 06'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE:BHVN)
Did Biohaven Ltd. Mislead Investors?
10:30am, Wednesday, 05'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE:BHVN)
Biohaven Ltd. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Biohaven Ltd.
08:05pm, Tuesday, 04'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
07:44pm, Tuesday, 04'th Mar 2025
NEW YORK , March 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd ("Biohaven" or the "Company") (NYSE: BHVN). Such investors are advised to cont
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biohaven Ltd. (BHVN) And Encourages Stockholders to Connect
12:00pm, Tuesday, 04'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE:BHVN)
Strong Immunoglobulin Reduction Data Positions Biohaven's BHV-1300 As Potential Autoimmune Therapy
01:09pm, Monday, 03'rd Mar 2025
On Monday, Biohaven Ltd. BHVN highlighted data from BHV-1300, showing rapid and deep reductions in total IgG for the potential treatment of autoimmune disease.
Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
07:31am, Monday, 03'rd Mar 2025
Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal antibody FcRn
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results
07:30am, Monday, 03'rd Mar 2025
Announced acceptance and Priority Review by the United States Food and Drug Administration (FDA) of the new drug application (NDA) for troriluzole in all-genotype spinocerebellar ataxia; expected Pres
